Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028 - Visiongain Report

Tuesday, June 12, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, June 12, 2018 /PRNewswire/ --

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators,

Biologics, Crohn's Disease, Ulcerative Colitis

The global inflammatory bowel diseases (IBD) drug market is estimated at $6.7bn in 2017 and $7.6bn in 2023. Biologic therapies held

57% share of the IBD market in 2017. The antibiotics segment of the IBD market is estimated to grow at a CAGR of 6.3% from 2018-2023.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 196-page report you will receive 141 charts- all unavailable elsewhere.

The 196-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2018-2028

• Submarket forecasts from 2018-2028: • Biologics • Aminosalicylates • Antibiotics • Corticosteroids • Immunomodulators

• Revenue forecast from 2018-2028 for 17 leading products: • Humira • Remicade • Lialda • Asacol • Pentasa • Xifaxan • Cimzia • Tysabri • Simponi • Canasa/Salofalk • Entyvio • Apriso • Medrol • Neoral • Entocort • Uceris • Azulfidine

• Revenue forecasts from 2018-2028 for 11 countries: • US Japan Germany, France, UK, Spain and Italy (EU5) Brazil, Russia, India and China (BRIC)

• Discussions on research and development, including drug candidates in these classes: • Interleukin (IL) inhibitors • Cell-adhesion molecule (CAM) inhibitors • TNF-alpha inhibitors • Stem cell therapies • JAK inhibitors • Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the IBD market. Moreover, this report discusses factors that drive and restrain the IBD market.

Visiongain's study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis.

To request a report overview of this report, please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website : https://www.visiongain.com/Report/2208/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2018-2028

Companies Listed 

4SC Abbott Laboratories AbbVie Ablynx Actavis Active Biotech Ajinomoto Alfasigma Group Allergan Almirall Amgen Aptalis Pharmaceuticals Astellas AstraZeneca Athersys Atlantic Healthcare Avaxia Biologics BioLineRx Biosafe Boehringer Ingelheim Calico Celgene Celltrion Centocor Ortho Biotech Cipla Coherus Biosciences Coronado Biosciences Cosmo Pharmaceuticals Dr. Falk Pharma Eddingpharm Elan Pharmaceuticals Epirus Biopharmaceuticals Ferring Forest Laboratories Galapagos Giaconda Google Harbor Biosciences Hospira Immunic InDex Pharmaceuticals Infinity Pharmaceuticals Isis Pharmaceuticals Janssen Biotech Johnson & Johnson Kissei Pharmaceutical Co., Ltd LG Sciences Lupin MedImmune Mochida Mutare Health Mylan Pharmaceuticals Neovacs Nisshin Kyorin Nogra Pharma NovaMedica Novartis Oncobiologics Ortho Biotech Osiris Therapeutics Otsuka Ovamed Palau Pharma Par Pharmaceuticals Pendopharm Perrigo Pfenex Pfizer Pharmascience Pluristem Therapeutics Qu Biologics Quest Diagnostics Ranbaxy Laboratories Receptos RedHill Biopharma Reliance Life Sciences Roche Salix Pharmaceuticals Sandoz Sanofi Santarus Sequella Shire Pharmaceuticals Sigmoid Pharma Soligenix SonarMD Takeda Pharmaceuticals Teva Pharmaceutical Industries TiGenix Toray Industries Torrent Pharmaceuticals Ltd. TxCell UCB Valeant Warner Chilcott Zeria Pharmaceutical Zydus Cadila

To see a report overview, please e-mail Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store